The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Nature

Volumn 537, Issue 7618, 2016, Pages 50-56

  Sevigny, Jeff ^a   Chiao, Ping ^a   Bussière, Thierry ^a   Weinreb, Paul H ^a   Williams, Leslie ^a   Maier, Marcel ^b   Dunstan, Robert ^a   Salloway, Stephen ^c   Chen, Tianle ^a   Ling, Yan ^a   O'Gorman, John ^a   Qian, Fang ^a   Arastu, Mahin ^a   Li, Mingwei ^a   Chollate, Sowmya ^a   Brennan, Melanie S ^a   Quintero Monzon, Omar ^a   Scannevin, Robert H ^a   Arnold, H Moore ^a   Engber, Thomas ^a   Rhodes, Kenneth ^a   Ferrero, James ^a   Hang, Yaming ^a   Mikulskis, Alvydas ^a   Grimm, Jan ^b   Hock, Christoph ^b,d   Nitsch, Roger M ^b,d   Sandrock, Alfred ^a   more..

^a BIOGEN   (United States)

^b Neurimmune Holding AG   (Switzerland)

^c BUTLER HOSPITAL   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; ALANINE AMINOTRANSFERASE; AMYLOID BETA PROTEIN; ASPARTATE AMINOTRANSFERASE; BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; FLORBETAPIR F 18; MEMANTINE; PLACEBO; AMYLOID; MONOCLONAL ANTIBODY;

ANTIBODY; BRAIN; CHEMICAL BINDING; DISEASE INCIDENCE; DISEASE TREATMENT; NERVOUS SYSTEM DISORDER; NEUROLOGY; PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL MODEL; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN; BRAIN EDEMA; BRAIN RADIOGRAPHY; CLINICAL DEMENTIA RATING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EC50; ELIMINATION HALF-LIFE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINI MENTAL STATE EXAMINATION; MOUSE; MULTICENTER STUDY; NAUSEA; NEUROIMAGING; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SIDEROSIS; SINGLE DRUG DOSE; TRANSGENIC ANIMAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PLAQUE, AMYLOID; PROTEIN AGGREGATION, PATHOLOGICAL; PSYCHOLOGY; SOLUBILITY; TRANSGENIC MOUSE; VERY ELDERLY;

MUS MUSCULUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MODELS, BIOLOGICAL; PLAQUE, AMYLOID; PROTEIN AGGREGATION, PATHOLOGICAL; SOLUBILITY;

EID: 84985896386     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature19323     Document Type: Article

References (41)

1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
2. Hardy, J. A. & Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
3. Ising, C., Stanley, M. & Holtzman, D. M. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. Clin. Pharmacol. Ther. 98, 469-471 (2015).
4. Selkoe, D. J. The therapeutics of Alzheimer's disease: where we stand and where we are heading. Ann. Neurol. 74, 328-336 (2013).
5. Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer's disease drugdevelopment pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37 (2014).
6. Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321 (2014).
7. Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333 (2014).
8. Ferrero, J. et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimers Dement (N Y) (in the press).
9. Sevigny, J. et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis. Assoc. Disord. 30, 1-7 (2016).
10. Landau, S. M. et al. Amyloid- imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J. Nucl. Med. 54, 70-77 (2013).
11. Banks, W. A. et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23, 2223-2226 (2002).
12. Levites, Y. et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J. 20, 2576-2578 (2006).
13. Bard, F. et al. Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919 (2000).
14. Bohrmann, B.et al. Gantenerumab: a novel human anti-A antibody demonstrates sustained cerebral amyloid- binding and elicits cell-mediated removal of human amyloid-. J. Alzheimers Dis. 28, 49-69 (2012).
15. Villemagne, V. L. et al. Amyloid deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357-367 (2013).
16. Ostrowitzki, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198-207 (2012).
17. Sperling, R. et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241-249 (2012).
18. Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloidmodifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367-385 (2011).
19. Barakos, J. et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am. J. Neuroradiol. 34, 1958-1965 (2013).
20. Zago, W. et al. Vascular alterations in PDAPP mice after anti-A immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9 (Suppl), S105-S115 (2013).
21. Wang, A., Das, P., Switzer, R. C., III, Golde, T. E. & Jankowsky, J. L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31, 4124-4136 (2011).
22. Boche, D. et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131, 3299-3310 (2008).
23. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007).
24. Kayed, R. & Lasagna-Reeves, C. A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33 (Suppl 1), S67-S78 (2013).
25. Benilova, I., Karran, E. & De Strooper, B. The toxic Aoligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
26. Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012-4017 (2009).
27. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
28. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A-42 hotspots around plaques. Nat. Commun. 6, 6176 (2015).
29. Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA 108, 5819-5824 (2011).
30. Kastanenka, K. et al. Amelioration of calcium dyshomeostasis by immunotherapy with BIIB037 in Tg2576 mice. Alzheimers Dement. 9, P508 (2013).
31. Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V. & Hooper, N. M. Amyloid- receptors: the good, the bad, and the prion protein. J. Biol. Chem. 291, 3174-3183 (2016).
32. Morkuniene, R. et al. Small A-1-42 oligomer-induced membrane depolarization of neuronal and microglial cells: role of N-methyl-d-aspartate receptors. J. Neurosci. Res. 93, 475-486 (2015).
33. Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a oligomer bound to cellular prion protein. Neuron 79, 887-902 (2013).
34. Derby, C. A. et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology 80, 1307-1314 (2013).
35. Dubois, B. et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9, 1118-1127 (2010).
36. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269 (2011).
37. Eli Lilly and Company. Amyvid Prescribing Information. http://www.lilly.com. (2013).
38. Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- plaques: a prospective cohort study. Lancet Neurol. 11, 669-678 (2012).
39. Hock, C. et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8, 1270-1275 (2002).
40. Tao, M. H. & Morrison, S. L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595-2601 (1989).
41. Johnson-Wood, K. et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 1550-1555 (1997).